Article
Oncology
Tae Won Kim, Howard A. Burris, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Summary: This study evaluated the first-in-human use of MOXR0916, a humanized monoclonal antibody, in the treatment of advanced solid tumors. The results showed that MOXR0916 was well tolerated and demonstrated evidence of tumor immune activation. Although objective responses were rare with monotherapy, further investigation in combination with PD-1/PD-L1 antagonists is warranted.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Elizabeth J. Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, Maria Vieito, Rowan E. Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E. Janik, Jason Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M. Mehnert
Summary: INCAGN01949, a fully human anti-OX40 agonist monoclonal antibody, showed no safety concerns as monotherapy in patients with advanced solid tumors, but limited tumor responses and pharmacodynamic effects on T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying Chen, Jincheng Wu, Sarah M. McWhirter, Thomas Mueller, Nitya Nair, Jason J. Luke
Summary: This study assessed the safety, pharmacokinetics, and efficacy of MIW815, a novel cyclic dinucleotide, in patients with advanced/metastatic cancers. Results showed that MIW815 was well tolerated, but had limited clinical activity as a single agent. However, evidence of systemic immune activation was observed.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sophie Postel-Vinay, Vincent K. Lam, Willeke Ros, Todd M. Bauer, Aaron R. Hansen, Daniel C. Cho, F. Stephen Hodi, Jan H. M. Schellens, Jennifer K. Litton, Sandrine Aspeslagh, Karen A. Autio, Frans L. Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M. Paul, Christoph M. Ahlers, Helen Zhou, Herbert Struemper, Shelby A. Gorman, Maura Watmuff, Kaitlin M. Yablonski, Niranjan Yanamandra, Michael J. Chisamore, Emmett Schmidt, Axel Hoos, Aurelien Marabelle, Jeffrey S. Weber, John Heymach
Summary: The ENGAGE-1 study evaluated the use of GSK3174998, an OX40 agonistic monoclonal antibody, alone or in combination with pembrolizumab in patients with advanced solid tumors. The combination therapy demonstrated good safety and tolerability, but limited clinical activity, suggesting that further development may not be warranted.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Multidisciplinary Sciences
Hui-Jen Tsai, Her-Shyong Shiah, Jang-Yang Chang, Wu-Chou Su, Nai-Jung Chiang, Li-Tzong Chen
Summary: This study determined the maximal tolerated dose (MTD) of S-1 when combined with sorafenib for refractory solid tumors to be 30 mg/m(2) bid. Some patients achieved durable partial response or stable disease with this regimen. Further phase II studies are warranted to evaluate the efficacy of this combination in advanced pNET and colon cancer.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Andrew L. Coveler, David C. Smith, Tycel Phillips, Brendan D. Curti, Sanjay Goel, Amitkumar N. Mehta, Timothy M. Kuzel, Svetomir N. Markovic, Olivier Rixe, David L. Bajor, Thomas F. Gajewski, Martin Gutierrez, Hun Ju Lee, Ajay K. Gopal, Paolo Caimi, Elisabeth Heath, John A. Thompson, Sahar Ansari, Celine Jacquemont, Ariel Topletz-Erickson, Peigen Zhou, Michael W. Schmitt, Juneko E. Grilley-Olson
Summary: SEA-CD40, an investigational antibody that activates CD40, demonstrated tolerability and potent immune activation in patients with solid tumors and lymphoma, showing evidence of antitumor activity. Further evaluation of SEA-CD40 as a component of combination therapy is warranted.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
James J. Harding, Melinda Telli, Pamela Munster, Martin H. Voss, Jeffrey R. Infante, Angela DeMichele, Mark Dunphy, Mai H. Le, Chris Molineaux, Keith Orford, Frank Parlati, Sam H. Whiting, Mark K. Bennett, Nizar M. Tannir, Funda Meric-Bernstam
Summary: The oral first-in-class glutaminase inhibitor telaglenastat was found to be safe with a favorable PK/PD profile and showed promise of antitumor activity in treatment-refractory solid tumor patients. Expansion cohorts demonstrated a disease control rate of 43% with a defined recommended phase II dose of 800 mg twice-daily. These results support further clinical development of telaglenastat.
CLINICAL CANCER RESEARCH
(2021)
Correction
Oncology
Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H. I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Mueller, Nitya Nair, Jason J. Luke
Summary: In the original version of the article, author Thomas W. Dubensky was mistakenly omitted from the author list. This error has been corrected in the latest online versions, and the author contributions and disclosures have been updated accordingly. The authors regret this mistake.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Martin Gutierrez, Victor Moreno, Kimberley M. Heinhuis, Anthony J. Olszanski, Anna Spreafico, Michael Ong, Quincy Chu, Richard D. Carvajal, Jose Trigo, Maria Ochoa De Olza, Mariano Provencio, Filip Yves De Vos, Filippo De Braud, Stephen Leong, Deanne Lathers, Rui Wang, Palani Ravindran, Yan Feng, Praveen Aanur, Ignacio Melero
Summary: This study evaluated the safety and activity of BMS-986178 in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors. The results showed a manageable safety profile, but no clear efficacy signal was observed above that expected for nivolumab and/or ipilimumab.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Amita Patnaik, Erika Hamilton, Yan Xing, Drew W. Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui
Summary: This study examines the safety and antitumor efficacy of a novel CDK4/6 inhibitor, FCN-437c, in patients with advanced solid tumors. The results show promising signs of durable tumor response and disease control. Further research is needed to investigate the safety and efficacy of FCN-437c.
Article
Oncology
Her-Shyong Shiah, Nai-Jung Chiang, Chia-Chi Lin, Chia-Jui Yen, Hui-Jen Tsai, Shang-Yin Wu, Wu-Chou Su, Kwang-Yu Chang, Ching-Chiung Wang, Jang-Yang Chang, Li-Tzong Chen
Summary: The novel microtubule inhibitor SCB01A has vascular disrupting activity and is safe and tolerable in patients with solid tumors, with a maximum tolerated dose of 24 mg/m(2) every 21 days and a half-life of approximately 2.5 hours. Treatment-related adverse events included anemia, nausea, vomiting, and some patients experienced neurotoxicity.
Article
Oncology
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Summary: This study evaluated the efficacy and tolerability of avelumab in Chinese patients. The results showed that avelumab at different doses can stabilize the disease and have partial responses in some patients' tumors.
Article
Oncology
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Summary: This study evaluated the safety and pharmacokinetics of avelumab in Chinese patients with advanced solid tumors. The results were consistent with previous global studies, showing some therapeutic effects in Chinese patients.
Article
Oncology
Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, Shunji Takahashi, John Sarantopoulos, Andrea Varga, Joseph A. D'Alessio, Tinya Abrams, Qing Sheng, Eugene Youchin Tan, Maria Santos Rosa, Juan Gonzalez-Maffe, Janna Sand-Dejmek, Claire Fabre, Miguel Martin
Summary: This study investigated the safety, tolerability, pharmacokinetics, and preliminary efficacy of PCA062 in patients with solid tumors. The findings showed limited antitumor activity at the maximum tolerated dose of PCA062, and no correlation between tumor P-cadherin expression and clinical efficacy.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Oncology
Meghan J. Mooradian, James M. Cleary, Anita Giobbie-Hurder, Lancia N. F. Darville, Aparna Parikh, Elizabeth I. Buchbinder, Justine V. Cohen, Donald P. Lawrence, Geoffrey I. Shapiro, Harold Keer, Helen X. X. Chen, Susan Percy Ivy, Keiran S. M. Smalley, John M. Koomen, Ryan J. Sullivan
Summary: This study showed that the combination of HSP90 inhibitor AT13387 with dabrafenib and trametinib was safe and led to modest disease control in heavily pretreated patients with BRAF V600E/K-mutant solid tumors. Further research is needed to identify tumor types and resistance mechanisms that are most sensitive to this approach.
